Aisling Capital Management
Aisling Capital Management reported 14 stocks worth $299M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are BBIO (67.9%), SNDX (8.3%) and CMPS (7.2%). Compared with Q2 2026, the fund added to CMPS and VTVT and trimmed BBIO, BCAX and SRRK.
Latest filing: what Aisling Capital Management did in Q3 2026
vs Q2 2026None
None
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() BBIO Bridgebio Pharma Inc | $203M | 67.9% | 3.1M | −1.5M (−33%) | 8 of 8 | |
| 2 | ![]() SNDX Syndax Pharmaceuticals Inc | $24.8M | 8.3% | 1.3M | No change | 8 of 8 | |
| 3 | ![]() CMPS Compass Pathways PLC | $21.6M | 7.2% | 1.7M | +300K (+21%) | 8 of 8 | |
| 4 | ![]() GLUE Monte Rosa Therapeutics Inc | $18.6M | 6.2% | 1.6M | No change | 8 of 8 | |
| 5 | ![]() BCAX Bicara Therapeutics Inc | $10.2M | 3.4% | 549K | −20K (−4%) | 8 of 8 | |
| 6 | ![]() URGN Urogen Pharma Ltd | $4.4M | 1.5% | 108K | No change | 4 of 8 | |
| 7 | ![]() BBOT Bridgebio Oncology Therapeut | $4.1M | 1.4% | 1M | No change | 5 of 8 | |
| 8 | ![]() EPRX Eupraxia Pharmaceuticals Inc | $3M | 1.0% | 325K | No change | 3 of 8 | |
| 9 | ![]() BMEA Biomea Fusion Inc | $2.7M | 0.9% | 2M | No change | 8 of 8 | |
| 10 | ![]() ACRS Aclaris Therapeutics Inc | $2.3M | 0.8% | 434K | No change | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 12, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Aisling Capital Management 13F FAQ
What does Aisling Capital Management own?
Aisling Capital Management reported 14 stocks worth $299M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are BBIO (67.9%), SNDX (8.3%) and CMPS (7.2%). The table above lists every position in the filing (the top 10 without an account).
What did Aisling Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 0 new positions, 2 added to, 3 trimmed and 0 sold out.
When will Aisling Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Aisling Capital Management's portfolio worth?
The Q3 2026 filing reports $299M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.











